We are so proud of our MIA Co-Medical Directors, Prof Georgina Long AO and Prof Richard Scolyer AO, jointly named 2024 Australians of the Year.
The federal government has announced a new immunotherapy treatment for advanced melanoma patients has been added to PBS, significantly reducing the cost of the life-saving treatment.
A clinical trial, developed by MIA researchers in collaboration with international colleagues, has been named by prestigious journal Nature Medicine as one of 11 clinical trials likely to have the most impact on global medicine in the year ahead.
Prof Georgina Long and Prof Richard Scolyer have been named in Top 52 News Makers for 2023 by the Sydney Morning Herald 'Good Weekend' magazine.
Congratulations to MIA Co-Medical Directors, Professor Georgina Long AO and Professor Richard Scolyer AO, jointly named 2024 NSW Australian of the Year.
Read more about Melanoma Institute Australia highlights from The Society for Melanoma Research 2023 Congress held in Philadelphia.
Read more about Prof Georgina Long receiving the ESMO Women for Oncology Award 2023, and MIA's significant contribution to cancer research discussions during ESMO23 in Madrid.
“Research into the genetic drivers of skin cancer is critical” - MIA Co-Medical Directors Prof Georgina Long AO and Prof Richard Scolyer are co-authors on this study into the link between male pattern baldness and skin cancer.
MIA Co-Medical Directors address the National Press Club of Australia detailing world-first breakthroughs in applying melanoma science to Richard Scolyer’s brain cancer.
A contemporary overview of Cutaneous melanoma, co-authored by MIA, has been published in The Lancet, one of the world's leading medical journals.